Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239328 | 0.88 | DGAT2 (0.47) | P2RX3DGAT2KDRVNN1RXRA | |
| SCHEMBL20239198 | 0.83 | DGAT2 (0.37) | DGAT2VNN1MAPTHPGD | |
| SCHEMBL20239331 | 0.82 | PGR (0.43) | P2RX3GRIN1GRIN2BPGRHPGD | |
| SCHEMBL20239182 | 0.81 | DGAT2 (0.47) | DGAT2VNN1RXRAGRIN1GRIN2B | |
| SCHEMBL20239160 | 0.80 | PGR (0.37) | P2RX3KDRPGRMETLNPEP | |
| SCHEMBL20239325 | 0.79 | DGAT2 (0.45) | DGAT2VNN1MAPTHPGD | |
| SCHEMBL20239322 | 0.78 | DGAT2 (0.44) | DGAT2KDRVNN1RXRAGRIN1 | |
| SCHEMBL20239132 | 0.77 | DGAT2 (0.46) | DGAT2RXRAGRIN1GRIN2BMAPT | |
| SCHEMBL20239333 | 0.74 | DGAT2 (0.56) | P2RX3DGAT2KDRVNN1MET | |
| SCHEMBL18249754 | 0.73 | KDR (0.41) | P2RX3KDRPGRMETHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | P2RX3 2448/4885DGAT2 1/4885KDR 1382/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | P2RX3 1822/4885DGAT2 1/4885KDR 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.